CANCER THERAPIES: GATHERING PACE
Orano Med, a subsidiary of the Orano group, is seeking to develop a new generation of targeted cancer therapies using the unique properties of lead-212 (212Pb), a rare alpha-emitting radioisotope representing one of the most potent therapeutic payloads against cancer cells.
Discover our mission
HOPES FOR TARGETED ALPHA THERAPY
Targeted alpha therapy is a technology that combines lead-212 with various biological molecules (peptides, antibodies) to target cancer cells. It can therefore selectively recognize and destroy them, limiting the impact on surrounding healthy cells.
RELIABLE SUPPLY OF LEAD-212
In order to produce and distribute its lead-212 conjugated drugs, Orano Med has invested in a unique set of facilities: the Maurice Tubiana Laboratory (LMT) in Bessines (France), the Domestic Distribution & Purification Unit (DDPU) in Plano (Texas), and the first Alpha Therapy Laboratory (ATLab) in Brownsburg (Indiana).
ATLAB TO OPEN IN VALENCIENNES IN 2025
This will be Europe’s first industrial-scale pharmaceutical facility dedicated to the production of targeted alpha therapies using lead-212.
A DIVERSIFIED PORTFOLIO
The Orano Med pipeline consists of molecules developed in partnership or independently. Two candidate drugs are being clinically tested in humans:
- > A phase 2 clinical trial on neuroendocrine tumors with AlphaMedixTM;
- > A phase 1 clinical trial on various types of solid tumors with an anti-GRPR peptide as a targeting molecule.
ALPHAMEDIX™
which targets neuroendocrine tumors, is the most advanced drug developed by Orano Med.
ORANO MED IN FIGURES
- 120 employees in France and the United States
- 12 patented inventions
- 2 ongoing clinical trials
- 2 preclinical laboratories dedicated to developing alpha-particle therapies
- 1 global industrial platform for the production of lead-212
